Chapter II · 5 min read
The Demand
Search, social velocity, and the emerging treatments pulling demand forward.
Aesthetic Search Demand
Monthly search volume for top aesthetic terms
~246,000 people search for a medspa near them every month.
Botox follows at 201k. Lip filler at 110k. These aren't research queries — “near me” and “cost” modifiers signal booking-ready patients within 48 hours.
~246k
Medspa local-intent searches/mo (modeled aggregate)
201k
"Botox" monthly searches
Modeled aggregate of medspa local-intent queries; Google Keyword Planner / SEMrush anchors, 2024–2025. (Exact-match “medspa near me” ≈ 33k/mo.)
Velocity matters more than volume.
#looksmaxxing is accelerating at 6.2× — the fastest trend in our dataset. These aren't fringe curiosities; they're category-forming movements that predict procedure volume 12–18 months out.
TikTok + Instagram trend analytics, 12-month velocity window
The next wave is already here.
Biostimulators are displacing traditional HA fillers. Polynucleotides (salmon-DNA injections) are mainstream in Korea and entering the US. Skin boosters like Profhilo sit between filler and topical — an entirely new procedural category.
We track 14 emerging treatment trends by confidence and proximity.
Trend Arrival Timeline
2022
Already mainstream
2023
Rapid adoption
2024
Breaking through
2025
Emerging
2026+
On the horizon
Ongoing
Source: Medica Depot 2024, Galderma consensus, Loma Health, Revance filings, Google Trends
10
High-confidence trends
14
Total emerging trends tracked
Medica Depot 2024, Galderma consensus, Loma Health, Revance filings
Six catalysts will reshape the next three years.
A sixth neurotoxin compressing pricing. A triple-agonist driving facial restoration demand. A compounding sunset forcing clinics to pivot. These aren't hypothetical — they have FDA filing dates and sponsor timelines.
Regulatory & Pipeline Catalysts — 2025→2028
Compresses per-unit Botox pricing 5–10%
Forces gray-market clinics to pivot or close
6-month duration vs. Botox's 3–4 months
New HA microdroplet indications
Enforcement on unapproved regen products
24% body-weight reduction → facial restoration demand
Source: FDA filings, Eli Lilly / Revance / Hugel SEC disclosures, PRS Global Open
FDA filings, Eli Lilly / Revance / Hugel SEC disclosures, PRS Global Open
The GLP-1 Aesthetic Dividend
The popular take is that weight-loss drugs are emptying the gyms. They aren't — US gyms hit a record 77M members in 20247. What GLP-1s are actually collapsing is the structured-diet industry (Weight Watchers filed Chapter 11 in 2025, members 4.4M → 2.6M)6 — and, more usefully for medspas, they are manufacturing a brand-new aesthetic patient who never existed before.
The conversion funnel
The 50% effect-rate and the $1,800 unit are observed; the ~25% act-rate is the one modeled lever — bracketed 15–35%, which sets the $4–10B range.
The metric — and the 2028 step-up
Retatrutide (~24–28% weight loss vs ~21% for tirzepatide; FDA est. 2027–28)5 deepens the effect-rate as adoption keeps climbing — the dividend doesn't just grow, it steps up.
Observed = sourced + dated (numbered below). Modeled = the ~25% act-rate (bracketed 15–35%), the $-per-point elasticity, and 2028 adoption (~18%, extrapolated from the 6%→12% trajectory). The funnel math is shown in full — auditable, not a black box.
Three readings of the same data.
- 'Near me' and 'cost' searches are booking-ready — capture them with intent-matched pages.
- Social velocity (looksmaxxing, salmon-DNA) predicts procedure volume 12–18 months out.
- Six regulatory catalysts will move pricing and demand through 2028 — plan menu shifts now.
- 246k monthly 'med spa near me' searches — a large, growing top of funnel.
- GLP-1 scripts +587% (2019–24) is reshaping adjacent aesthetic demand.
- Emerging categories (biostimulators, polynucleotides) extend the runway.
- Track the six catalysts — Letybo (6th neurotoxin), Daxxify, retatrutide.
- Filler is softening (~1% YoY); biostimulators and skin boosters are rising.
- Match content to the searches that actually convert.